Drug Profile
Lipid replacement therapy - Lypro Biosciences
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Lypro Biosciences
- Class Lipids
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Barth syndrome
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Barth syndrome in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Barth-syndrome in USA
- 26 Jul 2016 Preclinical trials in Barth syndrome in USA (unspecified route)